FindTrial
Sign In

Analysis of the enzyme dihydropyrimidine dehydrogenase for the prevention of chemotoxicity in patients receiving fluoropyrimidine based chemotherapy at a tertiary care hospital in South India

Chemotoxicity and pre-treatment dihydropyrimidine dehydrogenase analysis in patients on fluoropyrimidine based chemotherapy at a tertiary care hospital in South India - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2026/03/106139
Enrollment
76
Registered
2026-03-13
Start date
Unknown
Completion date
Unknown
Last updated
2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C21- Malignant neoplasm of anus and anal canal Health Condition 2: C18- Malignant neoplasm of colon Health Condition 3: C15- Malignant neoplasm of esophagus Health Condition 4: C23- Malignant neoplasm of gallbladder Health Condition 5: C22- Malignant neoplasm of liver and intrahepatic bile ducts Health Condition 6: C17- Malignant neoplasm of small intestine Health Condition 7: C16- Malignant neoplasm of stomach

Interventions

Intervention1: Nil: Nil Intervention2: Nil: Nil Intervention3: Nil: Nil

Sponsors

Rajiv Gandhi University of Health Sciences
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Newly diagnosed cancer patients scheduled for fluoropyrimidine based chemotherapy

Exclusion criteria

Exclusion criteria: Participants not willing to provide informed consent, pregnant, and lactating mothers will be excluded from the study

Design outcomes

Primary

MeasureTime frame
1. Proportion of DPD deficiency in newly diagnosed cancer patients scheduled for fluoropyrimidine based therapy 2. genetic variant and mutational status in the study population 3. Correlation between DPD deficiency with pretreatment plasma uracil level 4. Association of genotype and phenotype with severity of chemotherapy-induced toxicity in Timepoint: 18 months—

Secondary

MeasureTime frame
Proportion of ADRsTimepoint: 18 months—

Countries

India

Contacts

Public ContactDr Kiran M

Vydehi Institute of Medical Sciences and RC

shashivk5@gmail.com8861085629

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Apr 4, 2026